Cancer Genome Landscapes

Over the past decade, comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer. For most cancer types, this landscape consists of a small number of “mountains” (genes altered in a high percentage of tumors) and a much larger number of “hills” (genes altered infrequently). To date, these studies have revealed ~140 genes that, when altered by intragenic mutations, can promote or “drive” tumorigenesis. A typical tumor contains two to eight of these “driver gene” mutations; the remaining mutations are passengers that confer no selective growth advantage. Driver genes can be classified into 12 signaling pathways that regulate three core cellular processes: cell fate, cell survival, and genome maintenance. A better understanding of these pathways is one of the most pressing needs in basic cancer research. Even now, however, our knowledge of cancer genomes is sufficient to guide the development of more effective approaches for reducing cancer morbidity and mortality.

[1]  W. M. Barclay Surgery , 1894, Bristol medico-chirurgical journal.

[2]  A. Chadli THE CANCER CELL , 1924, La Presse medicale.

[3]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[4]  R. Kerbel Growth dominance of the metastatic cancer cell: cellular and molecular aspects. , 1990, Advances in cancer research.

[5]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[6]  AC Tose Cell , 1993, Cell.

[7]  G. Capellá,et al.  Genetic heterogeneity of the c-K-ras locus in colorectal adenomas but not in adenocarcinomas. , 1993, Journal of the National Cancer Institute.

[8]  M. Gerretsen,et al.  Br. J. Cancer , 1993 .

[9]  Scott E. Kern,et al.  Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers , 1996, Nature Genetics.

[10]  Bert Vogelstein,et al.  Gatekeepers and caretakers , 1997, Nature.

[11]  Hans Clevers,et al.  Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC , 1997, Science.

[12]  R. Quatrano Genomics , 1998, Plant Cell.

[13]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[14]  김삼묘,et al.  “Bioinformatics” 특집을 내면서 , 2000 .

[15]  S. Elledge,et al.  The DNA damage response: putting checkpoints in perspective , 2000, Nature.

[16]  K. Kinzler,et al.  Genetic Testing-- Present and Future , 2000, Science.

[17]  S. Gallinger,et al.  Microsatellite instability, mismatch repair deficiency, and colorectal cancer. , 2001, Surgery.

[18]  Robert A. Weinberg,et al.  Metastasis genes: A progression puzzle , 2002, Nature.

[19]  Hans Clevers,et al.  The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells , 2002, Cell.

[20]  Mattias Höglund,et al.  Coping with complexity. multivariate analysis of tumor karyotypes. , 2002, Cancer genetics and cytogenetics.

[21]  Hans Clevers,et al.  Notch1 functions as a tumor suppressor in mouse skin , 2003, Nature Genetics.

[22]  Andrew P. Weng,et al.  Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia , 2004, Science.

[23]  J. Aster,et al.  T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling , 2004, Current opinion in hematology.

[24]  P. Armitage,et al.  The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.

[25]  D. Lane,et al.  Transcription — guarding the genome by sensing DNA damage , 2004, Nature Reviews Cancer.

[26]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[27]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[28]  Ericka Stricklin-Parker,et al.  Ann , 2005 .

[29]  H. Lane,et al.  ERBB receptors and cancer: the complexity of targeted inhibitors , 2005, Nature Reviews Cancer.

[30]  刘金明,et al.  IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .

[31]  Dominik Wodarz,et al.  Drug resistance in cancer: principles of emergence and prevention. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[33]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[34]  Lucio Luzzatto,et al.  A quantitative measurement of the human somatic mutation rate. , 2005, Cancer research.

[35]  Yan Zhang,et al.  CanPredict: a computational tool for predicting cancer-associated missense mutations , 2007, Nucleic Acids Res..

[36]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[37]  Daniel A. Haber,et al.  Epidermal growth factor receptor mutations in lung cancer , 2007, Nature Reviews Cancer.

[38]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[39]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[40]  James M. Roberts,et al.  CDK Inhibitors : Cell Cycle Regulators and Beyond , 2008 .

[41]  Martin A. Nowak,et al.  Comparative lesion sequencing provides insights into tumor evolution , 2008, Proceedings of the National Academy of Sciences.

[42]  C. Yeang,et al.  Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[43]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[44]  K. Kinzler,et al.  Epitope landscape in breast and colorectal cancer. , 2008, Cancer research.

[45]  John G Doench,et al.  Kinase requirements in human cells: I. Comparing kinase requirements across various cell types , 2008, Proceedings of the National Academy of Sciences.

[46]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[47]  Jeffrey Wyckoff,et al.  Differential enhancement of breast cancer cell motility and metastasis by helical and kinase domain mutations of class IA phosphoinositide 3-kinase. , 2009, Cancer research.

[48]  G. Parmigiani,et al.  Design and analysis issues in genome-wide somatic mutation studies of cancer. , 2009, Genomics.

[49]  T. Kunkel Evolving views of DNA replication (in)fidelity. , 2009, Cold Spring Harbor symposia on quantitative biology.

[50]  R. Rosenfeld Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[51]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[52]  Leyla Isik,et al.  Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. , 2009, Cancer research.

[53]  K. Kinzler,et al.  Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells , 2009, Science.

[54]  Ryan D. Morin,et al.  Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution , 2009, Nature.

[55]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[56]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[57]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[58]  Gurpreet W. Tang,et al.  Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.

[59]  Roberta Pereira NiquiniI,et al.  Rev Saúde Pública , 2010 .

[60]  Tian-Li Wang,et al.  Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.

[61]  Joshua F. McMichael,et al.  DNMT3A mutations in acute myeloid leukemia. , 2010, The New England journal of medicine.

[62]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[63]  Rational use of anticancer drugs and patient lawsuits in the state of São Paulo, Southeastern Brazil. , 2010, Revista de saude publica.

[64]  Andrew Menzies,et al.  The patterns and dynamics of genomic instability in metastatic pancreatic cancer , 2010, Nature.

[65]  Jeffrey W. Clark,et al.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. , 2010, The New England journal of medicine.

[66]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[67]  Raymond Sawaya,et al.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[69]  Richard Durrett,et al.  Evolution of Resistance and Progression to Disease during Clonal Expansion of Cancer , 2009 .

[70]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[71]  Silvio Barberato-Filho,et al.  Uso racional de medicamentos antineoplásicos y acciones judiciales en el estado de Sao Paulo, Sureste de Brasil , 2010 .

[72]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[73]  M. Kastan,et al.  Multiple roles of ATM in monitoring and maintaining DNA integrity , 2010, FEBS letters.

[74]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[75]  S. Gabriel,et al.  Advances in understanding cancer genomes through second-generation sequencing , 2010, Nature Reviews Genetics.

[76]  R. Reddel,et al.  Alternative lengthening of telomeres: models, mechanisms and implications , 2010, Nature Reviews Genetics.

[77]  Richard A. Moore,et al.  ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.

[78]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[79]  D. Brock Ethical and value issues in insurance coverage for cancer treatment. , 2010, The oncologist.

[80]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[81]  Michael A. Choti,et al.  DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors , 2011, Science.

[82]  Nikhil Wagle,et al.  Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[84]  Dennis B. Troup,et al.  NCBI GEO: archive for functional genomics data sets—10 years on , 2010, Nucleic Acids Res..

[85]  M. Pelizzola,et al.  The DNA methylome , 2011, FEBS letters.

[86]  Napoleone Ferrara,et al.  Developmental and pathological angiogenesis. , 2011, Annual review of cell and developmental biology.

[87]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[88]  Kristian Cibulskis,et al.  Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion , 2011, Nature Genetics.

[89]  P. J. van der Zaag,et al.  Targeted enrichment of genomic DNA regions for next-generation sequencing , 2011, Briefings in functional genomics.

[90]  Govind Bhagat,et al.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.

[91]  Raul Rabadan,et al.  Analysis of the Coding Genome of Diffuse Large B-Cell Lymphoma , 2011, Nature Genetics.

[92]  R. Gibbs,et al.  Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1 , 2011, Science.

[93]  Mehmet Toner,et al.  Circulating tumor cells: approaches to isolation and characterization , 2011, The Journal of cell biology.

[94]  J. Troge,et al.  Tumour evolution inferred by single-cell sequencing , 2011, Nature.

[95]  Zev A. Binder,et al.  The Genetic Landscape of the Childhood Cancer Medulloblastoma , 2011, Science.

[96]  A. Ashworth,et al.  Therapeutic potential of PARP inhibitors for metastatic breast cancer , 2011, Expert review of anticancer therapy.

[97]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[98]  Peter Greenwald,et al.  Biomarkers for early detection and as surrogate endpoints in cancer prevention trials: issues and opportunities. , 2011, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[99]  Zhengyan Kan,et al.  Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer , 2011, Nature Genetics.

[100]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[101]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[102]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[103]  Dai Fukumura,et al.  Scaling rules for diffusive drug delivery in tumor and normal tissues , 2011, Proceedings of the National Academy of Sciences.

[104]  R. McLendon,et al.  Altered Telomeres in Tumors with ATRX and DAXX Mutations , 2011, Science.

[105]  Richard Simon,et al.  Identifying cancer driver genes in tumor genome sequencing studies , 2011, Bioinform..

[106]  M. Stratton,et al.  Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.

[107]  Michael Gundry,et al.  Direct mutation analysis by high-throughput sequencing: from germline to low-abundant, somatic variants. , 2012, Mutation research.

[108]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[109]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[110]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[111]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[112]  Gerald C. Chu,et al.  Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism , 2012, Cell.

[113]  A. Børresen-Dale,et al.  The landscape of cancer genes and mutational processes in breast cancer , 2012, Nature.

[114]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[115]  Lilia M. Iakoucheva,et al.  Whole-Genome Sequencing in Autism Identifies Hot Spots for De Novo Germline Mutation , 2012, Cell.

[116]  C. Sander,et al.  Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.

[117]  Rachelle J Bienstock,et al.  Computational drug design targeting protein-protein interactions. , 2012, Current pharmaceutical design.

[118]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.

[119]  Michael A. Davies,et al.  Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents , 2012, Clinical Cancer Research.

[120]  Yuchen Jiao,et al.  Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. , 2012, Cancer discovery.

[121]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of human colon and rectal cancer , 2012, Nature.

[122]  Boping Zhou,et al.  Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma , 2012, Nature Genetics.

[123]  Norbert Perrimon,et al.  Signaling mechanisms controlling cell fate and embryonic patterning. , 2012, Cold Spring Harbor perspectives in biology.

[124]  Michael Wigler,et al.  A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions , 2012, Proceedings of the National Academy of Sciences.

[125]  Huanming Yang,et al.  Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor , 2012, Cell.

[126]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[127]  M. Meyerson,et al.  Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential , 2012, Science.

[128]  Meng Li,et al.  Somatic Mutations in the Chromatin Remodeling Gene ARID1A Occur in Several Tumor Types , 2011, Human mutation.

[129]  Lincoln D. Stein,et al.  Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes , 2012, Nature.

[130]  Robert Gentleman,et al.  Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.

[131]  E. Laurenti,et al.  Molecular and functional characterization of early human hematopoiesis , 2012, Annals of the New York Academy of Sciences.

[132]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[133]  Graham A. Colditz,et al.  Applying What We Know to Accelerate Cancer Prevention , 2012, Science Translational Medicine.

[134]  T. Hoppo,et al.  The mouse lymph node as an ectopic transplantation site for multiple tissues , 2012, Nature Biotechnology.

[135]  Joshua F. McMichael,et al.  Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition , 2012, Nature.

[136]  Li Ding,et al.  Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers , 2012, Cell.

[137]  Marc A. Beal,et al.  Whole genome sequencing for quantifying germline mutation frequency in humans and model species: cautious optimism. , 2012, Mutation research.

[138]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[139]  P. J. van der Zaag,et al.  Using a priori knowledge to align sequencing reads to their exact genomic position , 2011, Nucleic acids research.

[140]  J. Kirkwood,et al.  Immunotherapy of cancer in 2012 , 2012, CA: a cancer journal for clinicians.

[141]  Li Ding,et al.  RECURRENT MUTATIONS IN THE U2AF1 SPLICING FACTOR IN MYELODYSPLASTIC SYNDROMES , 2011, Nature Genetics.

[142]  R. Medema,et al.  Checkpoint control and cancer , 2012, Oncogene.

[143]  A. Viale,et al.  IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.

[144]  Johannes G. Reiter,et al.  The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers , 2012, Nature.

[145]  Gholamreza Haffari,et al.  Feature-based classifiers for somatic mutation detection in tumour–normal paired sequencing data , 2011, Bioinform..

[146]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[147]  Yun Ye,et al.  Association between KRAS codon 13 mutations and clinical response to anti-EGFR treatment in patients with metastatic colorectal cancer: results from a meta-analysis , 2012, Cancer Chemotherapy and Pharmacology.

[148]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[149]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[150]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[151]  A. Børresen-Dale,et al.  Mutational Processes Molding the Genomes of 21 Breast Cancers , 2012, Cell.

[152]  Lynda Chin,et al.  Highly Recurrent TERT Promoter Mutations in Human Melanoma , 2013, Science.

[153]  D. Schadendorf,et al.  TERT Promoter Mutations in Familial and Sporadic Melanoma , 2013, Science.

[154]  Andrea Sottoriva,et al.  Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. , 2013, Cancer research.

[155]  Andreas Keller,et al.  From next-generation sequencing alignments to accurate comparison and validation of single-nucleotide variants: the pibase software , 2012, Nucleic acids research.

[156]  B. Bernstein,et al.  Epigenetic Reprogramming in Cancer , 2013, Science.

[157]  Peter Donnelly,et al.  Germline mutations in the proof-reading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas , 2012, Nature Genetics.

[158]  Howard L McLeod,et al.  Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed , 2013, Science.

[159]  Giovanni Parmigiani,et al.  Half or more of the somatic mutations in cancers of self-renewing tissues originate prior to tumor initiation , 2013, Proceedings of the National Academy of Sciences.

[160]  I. Tomlinson,et al.  Whole-genome methylation analysis of benign and malignant colorectal tumours , 2013, The Journal of pathology.

[161]  Andrew M. K. Brown,et al.  Variable Clonal Repopulation Dynamics Influence Chemotherapy Response in Colorectal Cancer , 2013, Science.

[162]  William G. Wadsworth,et al.  This copy is for your personal, non-commercial use only. , 2014 .